Cancer-associated fibroblasts promote osimertinib resistance in non-small cell lung cancer cells via METTL1-mediated NET1 m7G modification - PubMed
a month ago
- #non-small cell lung cancer
- #osimertinib resistance
- #m7G modification
- Cancer-associated fibroblasts (CAFs) promote osimertinib resistance in non-small cell lung cancer (NSCLC) cells.
- CAFs elevate RNA m7G modification in NSCLC cells via methyltransferase 1 (METTL1).
- METTL1 is associated with NSCLC progression and poor prognosis.
- CAFs upregulate METTL1 in NSCLC cells by secreting HMGB1.
- Neuroepithelial cell transforming gene 1 (NET1) is identified as a target of METTL1.
- Enhanced m7G modification of NET1 increases its expression and activates the AKT/NF-κB pathway.
- Reducing m7G modification by METTL1 knockdown attenuates CAFs' effect on osimertinib resistance.
- The study highlights the role of m7G modification in cancer cell-TME communication and suggests potential therapeutic strategies.